Mode
Text Size
Log in / Sign up
N/A N=47 Randomized Treatment

Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery

Atelectasis · Pulmonary Infection · Chronic Obstructive Pulmonary Disease (COPD) · Pulmonary Disease · Hypoxemic Respiratory Failure

Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Forced Expiratory Volume at One Second (FEV1) Difference — 3.1; 3.1; 1.3; 1.4 Litres — p=0.88

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Bi-PAP (Device); Sham Bi-PAP (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Evangelismos Hospital
Primary completion
May 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Forced Expiratory Volume at One Second (FEV1) Difference
3.1; 3.1; 1.3; 1.4; 1.3; 1.7 0.88
PRIMARY
Forced Vital Capacity (FVC) Difference
3.4; 3.5; 1.3; 1.6; 1.5; 2.0 0.75
PRIMARY
Peak Expiratory Flow Rate (PEFR) Difference
376.9; 325.3; 146.9; 137.4; 166.0; 195.7 0.05
PRIMARY
SpO2 Difference
96.9; 96.9; 91.6; 92.6; 92.4; 95.2 0.83
PRIMARY
Number of Participants With Hypoxemia
5; 0; 0; 0; 0; 0
PRIMARY
Number of Participants With Atelectasis
3; 0; 3; 0; 3; 0
SECONDARY
Post-operative Pain
6.5; 6.5; 4.5; 5.3; 3.3; 3.5
SECONDARY
Days of Hospitalization
6; 6; 10; 10

Summary

The effect of biphasic positive airway pressure (Bi-PAP) at individualized pressures on the postoperative pulmonary recovery of morbidly obese patients (MOP) undergoing open bariatric surgery (OBS) and possible placebo device-related effects (sham-Bi-PAP) were investigated.

Eligibility Criteria

Inclusion Criteria

  • All patients have been Morbidly Obese (BMI> 40kg/m2) for at least 10 years
  • All patients had unsuccessfully tried to lose weight by other non-invasive means.
  • All patients enrolled were continuous positive airway pressure (CPAP) and Bi-PAP naïve and had no knowledge about the Bi-PAP apparatus prior to enrollment
  • All patients underwent OBS (gastroplasty by Mason or gastric bypass) by the same operating team
  • All patients were treated with the same standard anesthetic protocol

Exclusion Criteria

  • Cardiovascular and pulmonary disease not related to obesity status
  • Chronic renal disease
  • Patients who were initially enrolled but did not use the allocated device (Bi-PAP or Sham Bi-PAP) for at least 12 h daily were also excluded at a later point.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03438383). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search